abrdn Life Sciences Investors
HQL
59 hedge funds and large institutions have $60.2M invested in abrdn Life Sciences Investors in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
56% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 16
5% more funds holding
Funds holding: 56 → 59 (+3)
0.46% less ownership
Funds ownership: 15.02% → 14.56% (-0.46%)
1% less capital invested
Capital invested by funds: $61M → $60.2M (-$713K)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$1.05M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$669K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$551K |
| 4 |
NMC
Nine Masts Capital
Central,
Hong Kong
|
+$457K |
| 5 |
DA
Doliver Advisors
Houston,
Texas
|
+$357K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAN
Claraphi Advisory Network
Aliso Viejo,
United States
|
-$2.64M |
| 2 |
Morgan Stanley
New York
|
-$583K |
| 3 |
Cerity Partners
New York
|
-$192K |
| 4 |
LPL Financial
San Diego,
California
|
-$159K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
-$128K |
HQL Hedge Fund Activity: Q2 2018 in Review
59 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2018, worth a combined $60.2M — down 1.2% from $61M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new HQL positions and 5 closed out — a net gain of 3 holders — while 25 added to existing stakes and 16 trimmed.
The largest buyer was William Blair & Company, opening a new position worth an estimated $1.05M. The largest seller was Claraphi Advisory Network, cutting an estimated $2.64M.
- 59 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2018, up from 56 in Q1 2018.
- Funds reported $60.2M of abrdn Life Sciences Investors stock for Q2 2018, down 1.2% quarter-over-quarter.
- 8 funds opened new abrdn Life Sciences Investors positions in Q2 2018 and 5 closed out, a net change of +3 holders.
- The largest abrdn Life Sciences Investors buyer in Q2 2018 was William Blair & Company, an estimated $1.05M added.
- The largest abrdn Life Sciences Investors seller in Q2 2018 was Claraphi Advisory Network, an estimated $2.64M sold.
Based on aggregated 13F filings for Q2 2018.